secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK:        0000882796
Form:       8-K
Filed at:   2023-11-30T23:59:59+00:00
Accession:  0001171843-23-007357
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 7.01
LLM model:  deepseek-v4-flash:cloud@v2

BioCryst updates ORLADEYO Japan commercialization; new royalty tier at 80% above threshold
--------------------------------------------------------------------------------

- BioCryst Japan K.K. now handles all commercial promotion for ORLADEYO in Japan; Torii to conduct HAE disease awareness.
- Royalty amended: 20% on annual Japanese sales below a prespecified threshold, 80% on sales above that threshold.
- BioCryst assumes direct commercial activities for ORLADEYO in Japan via its subsidiary under updated Torii agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882796/000117184323007357/0001171843-23-007357-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882796/000117184323007357/f8k_113023.htm
  HTML page:      https://secwatch.observer/filing/0001171843-23-007357

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer